Hangzhou Just Biotherapeutics, of Shanghai, said it completed a $35 million series B+ financing round led by Hillhouse Capital with participation from its existing investors Temasek, Lilly Asia Ventures, Arch Venture Partners, Taikang and BOCGI Zheshang Capital. The company is working in a number of areas including the completion of an R&D center and manufacturing facility, establishing its R&D and clinical development capabilities and building a world-class team.